Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul H Frankel

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
The New England Journal of Medicine|August 2, 2003
Obesity and cancerPaul H Frankel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
Guideline for 5-alpha-reductase inhibitors in the prevention of prostate cancer is prematurePaul H Frankel, Przemyslaw Twardowski
Current Treatment Options in Oncology|March 5, 2016
New Approaches for Immune Directed Treatment for Ovarian CancerNicola Hardwick, Paul H Frankel, Mihaela Cristea
Statistics in Medicine|November 17, 2022
Explicit underdose control based on toxicity: Four points to considerPaul H Frankel, Elizabeth Garrett-Mayer, Mark D Krailo
Contemporary Clinical Trials|December 8, 2006
A permutation test for a weighted Kaplan-Meier estimator with application to the nutritional prevention of cancer trialPaul H Frankel, Mary E Reid, James R Marshall
The Journal of Nutrition|March 30, 2005
Epithelium-specific glutathione peroxidase, Gpx2, is involved in the prevention of intestinal inflammation in selenium-deficient miceR Steven Esworthy, Lixin Yang, Paul H Frankel, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 4, 2014
Using a single parameter to describe time-activity curvesCheuk S Kwok, Paul H Frankel, George Lopatin, et al.
The FEBS Journal|April 16, 2008
Collective behavior in gene regulation: the cell is an oscillator, the cell cycle a developmental processRobert R Klevecz, Caroline M Li, Ian Marcus, et al.
Journal of the National Cancer Institute|February 25, 2014
Baseline selenium and prostate cancer risk: comments and open questionsPaul H Frankel, Robert S Parker, Fred C Madsen, et al.
Contemporary Clinical Trials|January 13, 2023
Order of patient entry and outcomes in phase II clinical trials: A meta-analysis of individual patient dataCarolyn E Behrendt, Miguel A Villalona-Calero, Edward M Newman, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
The New England Journal of Medicine|August 2, 2003
Obesity and cancerPaul H Frankel
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
Guideline for 5-alpha-reductase inhibitors in the prevention of prostate cancer is prematurePaul H Frankel, Przemyslaw Twardowski
Current Treatment Options in Oncology|March 5, 2016
New Approaches for Immune Directed Treatment for Ovarian CancerNicola Hardwick, Paul H Frankel, Mihaela Cristea
Statistics in Medicine|November 17, 2022
Explicit underdose control based on toxicity: Four points to considerPaul H Frankel, Elizabeth Garrett-Mayer, Mark D Krailo
Contemporary Clinical Trials|December 8, 2006
A permutation test for a weighted Kaplan-Meier estimator with application to the nutritional prevention of cancer trialPaul H Frankel, Mary E Reid, James R Marshall
The Journal of Nutrition|March 30, 2005
Epithelium-specific glutathione peroxidase, Gpx2, is involved in the prevention of intestinal inflammation in selenium-deficient miceR Steven Esworthy, Lixin Yang, Paul H Frankel, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 4, 2014
Using a single parameter to describe time-activity curvesCheuk S Kwok, Paul H Frankel, George Lopatin, et al.
The FEBS Journal|April 16, 2008
Collective behavior in gene regulation: the cell is an oscillator, the cell cycle a developmental processRobert R Klevecz, Caroline M Li, Ian Marcus, et al.
Journal of the National Cancer Institute|February 25, 2014
Baseline selenium and prostate cancer risk: comments and open questionsPaul H Frankel, Robert S Parker, Fred C Madsen, et al.
Contemporary Clinical Trials|January 13, 2023
Order of patient entry and outcomes in phase II clinical trials: A meta-analysis of individual patient dataCarolyn E Behrendt, Miguel A Villalona-Calero, Edward M Newman, et al.
Pageof 6